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1. Introduction  
Depressive and anxiety disorders are a major burden on society. Mood disorders affect 7% of 
the world’s population, while severe forms of depression impact 2-5% of the US population 
(Murray and Lopez, 1996; Samuels and Hen, 2011). Furthermore, approximately 32-35 million 
adults in the US population (16%) experience an episode of major depression in their lifetime 
(Kessler et al., 2003). While many classes of drugs with antidepressant activity have been 
developed and approved (Wong et al., 2010), many patients do not respond to treatment 
(Trivedi et al., 2006). Therefore it is critical for basic research to develop animal models that 
present behavioral, neurochemical and brain morphological phenotypes reminiscent of 
depression and anxiety. Given that anxiety and depression have a high comorbidity with co-
occurrence rates up to 60% in patients (Leonardo and Hen, 2006), animal models that present 
signs of both diseases could potentially be the most useful. 
When prescribing medication, there is increasing pressure on clinicians to follow decision-
tree medical algorithms, such as the Texas Medication Algorithm project (TMAP), in 
attempts to combat depression in patients that are non-responsive to initial lines of 
treatment. These involve multiple levels of treatments, each with varying success. Recently, 
STAR*D, a large study designed to mirror clinical practice, was conducted at 25 different 
sites. The study enrolled over 4000 patients with a broad range of symptoms and involved 4 
possible steps for treatment (Fava and Covino, 2007). If patients failed to achieve remission 
at any level, they would be randomized for the next step of treatment. As patients moved 
from levels 2-4 of treatment, remission rates dropped dramatically (from approximately 35% 
at level 2 to 16% at level 4). Therefore, failure to achieve remission with 2 consecutive 
treatments is associated with very low remission rates in subsequent treatments. This 
suggests that the usefulness of current lines of treatment is limited and underscores the need 
for discovery of new treatments. 
The present review defines the notion of non-response/resistance to antidepressants in 
human and the factors that may influence these clinical aspects. Then it focuses on the 
preclinical study aimed at developing relevant animal models of resistance including the 
unpredictable chronic mild stress (UCMS), the social interaction test and the repeated 
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corticosterone exposure. Is it worthwhile to model depression in rodents? Clearly many 
signs of depression such as guilt, feelings of worthlessness and recurrent thoughts of death 
are going to be features specific to humans. It is not possible to question animals and give 
them a score on the Hamilton Rating Scale for Depression (HAM-D) as is often done with 
humans. However, many other aspects of depressive disorders have been replicated in the 
laboratory setting. This review also describes the recent findings about the cellular and 
molecular bases of non-response and resistance to antidepressants. Finally, it synthesizes 
our current knowledge on the therapeutic activity of a new generation of antidepressant 
drugs, the triple reuptake inhibitors (TRIs). These pharmacological agents, that 
simultaneously increase serotonergic, noradrenergic and dopaminergic neurotransmissions, 
are believed to produce greater antidepressant effects than single- or dual acting-agents 
such as the selective serotonin reuptake inhibitors (SSRIs) or the serotonin/norepinephrine 
reuptake inhibitors (SNRIs) (Skolnick et al., 2003; Guiard et al., 2009). Indeed, by treating 
core and/or residual symptoms of depression, TRIs might provide an interesting alternative 
to the 50% of depressive individuals that do not respond adequately to conventional 
antidepressants.  
2. Treatment-resistant depression (TRD) – Clinical aspects 
SSRIs and SNRIs are the most commonly prescribed drugs for the treatment of major 
depression (MD). Despite recent advances in the pharmacological treatment of depression, 
60% of patients with unipolar major depressive episodes do not respond adequately to 
SSRIs/SNRIs. Furthermore, as observed in the STAR*D study, treatment resistant 
depression, i.e. major depressive episodes resistant to antidepressant treatment, as defined 
by the lack of response to two consecutive and different antidepressant drugs, prescribed at 
adequate dosages and for adequate durations (Connolly and Thase 2011; Ruhé et al., 2011), 
occurs in 20% to 30% of MD patients (Gaynes et al., 2008). As compared with major 
depressive episode responsive to antidepressant drugs, treatment resistant episodes are 
associated with a 2 to 3-times increase in the use of other psychotropic medications. More 
importantly, the global medical costs associated with resistance are 6-times higher than 
those associated with non treatment-resistant depression ($42,344 vs. $6512) and the total 
depression-related costs of resistance are 19-times higher than those of patients with non-
treatment-resistant MD ($28,001 vs. $1455) (Crown et al., 2002; Ivanova et al., 2010). 
2.1 From non response to resistance: Definitions 
Response to an antidepressant is usually characterized by a decrease of at least 50% from the 
baseline score in a depression scale at the end of the trial endpoint (Riso et al., 1997). 
Measurement of depression severity and antidepressant responsiveness is usually 
performed using scales such as the HAM-D, MADRS (Montgomery-Åsberg Depression 
Rating Scale), QUIDS (Quick Inventory of Depressive Symptomatology) and CGIs (Clinical 
Global Impression). However, such a decrease does not qualify a patient as remitted but 
only as responder, as patients with high scores (>30) at the HAM-D scale would not be 
consider as remitted (Nierenberg et al., 2001). Oppositely, the threshold for non-response is 
always hard to set and can exclude various sub-groups such as “non-remitted” responders 
as well as partial responders. Usually, non-response is considered to be a decrease of less 
than 25% on depression scale measurements, but in some studies, failure of remission can be 
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set as the threshold to define treatment failure. For instance, one of the largest studies 
aiming at defining effectiveness of SSRIs and identifying predictors of symptom remission 
was STAR*D, and its criteria were as following: an exit HAM-D score ≤7 qualified for 
remission and a reduction of more than 50% in baseline QIDS-SR (Quick Inventory of 
Depressive Symptomatology-Self Report) at the last assessment was defined as response 
(Hollon et al., 2005; Trivedi et al., 2006).  
The definition of treatment resistance depressed (TRD) patients is still a matter of debate, 
and numerous definitions have been proposed based either on the duration of the illness, 
use of augmentation strategies or extent of treatment (Souery et al., 1999; Sackeim, 2001; 
Fagiolini and Kupfer, 2003), resulting in a possible under-estimation of TRD prevalence 
(Nemeroff et al., 2007). Furthermore, our knowledge of TRD is also based on naturalistic 
follow-up studies of the outcome of depressive disorders in general (Souery et al., 1999). The 
simplest and most widely used definition of resistance is when a current episode of 
depression has not benefited from at least 2 adequate trials (i.e. appropriate dose, duration 
and extent) of different classes of antidepressants (Ananth, 1998; Rush et al., 2003; Keller, 
2005). Despite limitations (Berlim and Turecki, 2007a), this definition is the most widely 
accepted. Furthermore, this definition benefits from the strong support brought by the 
STAR*D study, where response rates after failure to 2 antidepressant strategies dramatically 
decrease (Ruhé et al., 2006b; Rush et al., 2006). 
Staging methods for classifications of TRD have been proposed and reviewed by several 
authors (Berlim and Turecki, 2007b; Hetrick et al., 2008) and consist of graduating stages of 
resistance based on response to one or more different therapeutic strategies (Thase and Rush, 
1997, see Table 1), but can also include chronic aspects of resistance (European Staging Model: 
Souery et al., 1999; Antidepressant Treatment History Form (ATHF): Sackeim et al., 1990; 
Oquendo et al., 2003). More recent models do not implicate an antidepressant hierarchy: for 
instance, the Massachusetts General Hospital staging method is a more flexible model, based 
on the number of antidepressant trials performed and their possible adjustments, without 
taking into consideration the pharmacological class differences of each trial (Fava, 2003). 
However this does not include duration of the disease. Yet one of the most comprehensive 
models proposed may be the Maudsley staging method for TRD (MSM). It incorporates the 
number of failed treatment trials, the chronicity of the disease and also includes measurements 
of disease severity as an important cofactor (Fekadu et al., 2009a,b).  Ruhé et al. (2011) recently 
compared various staging methods and concluded that overall MSM displays high validity, 
but its reliability and sensitivity needs to be confirmed in other larger studies.  
 
Stage Definition 
0 Yet no adequate medication trials. 
I Non-response to 1 adequate trial of antidepressant 
II 
Stage I + non-response to 1 adequate trial of single antidepressant belonging to  
a distinct pharmacological class from that used in class I 
III Stage II + non-response to an adequate trial of a TCA 
IV Stage III + non-response to an adequate trial of a MAOI 
V Stage IV + non-response to electroconvulsive therapy 
Table 1. Staging method, adapted from Thase and Rush, 1997. 
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2.2 Factors implicated in non-response/resistance 
Clinical, biological, and sociodemographic variables have been studied in relation to 
resistance to antidepressant treatment. However, due to sample size of the studies and 
methodological variablilities in defining resistance, results are not necessarily consistent and 
reliable (Berlim and Turecki, 2007a,b; Kornstein et Schneider, 2001).  
2.2.1 Sex differences in non-reponse/resistance 
Women are twice as likely to experience MD as men (Kornstein et al., 2000) and four times 
as likely to have recurrent MD (Perugi et al., 1990). Women also have more MD symptoms 
and greater symptom severity (Angst and Dobler-Mikola, 1984; Frank et al., 1988; Young et 
al., 1990). Therefore, there is often a preponderance of women in studies, including 
treatment-resistant depression studies, but there is no evidence that sex is a predictor for 
resistance (Sotsky et al., 1991; Souery et al., 2007). The only sparse and slight evidence of sex 
differences might be in response to first antidepressant treatment (Sloan and Korstein, 2003), 
where women seem to respond slightly less to tricyclics (Hamilton et al., 1996), but respond 
similarly or slightly better to SSRI treatment (Papakostas et al., 2006; Kornstein et al., 2006). 
No sex difference to ECT treatment has been reported (Bloch et al., 2004).  
2.2.2 Age of onset  
There is evidence that age of onset may predispose to a higher risk to develop TRD. Indeed, 
early onset of depression has been associated with a chronic course of the illness (Akiskal et 
al., 1981), and often results in higher severity of the disease as well as higher rates of 
comorbidity (Klein et al., 1999). Furthermore, early onset of first depressive episode has 
been considered as a risk factor in recent studies including large sample of patients (Dudek 
et al., 2010; Souery et al., 2007). Onset of depression in patients >60 years has been associated 
with a greater likelihood of psychotic symptoms and vascular brain changes that may 
increase the risk to develop to resistance (Kornstein et Schneider, 2001) Similar efficacy rates 
for antidepressant and psychological therapies have been reported in older adults and those 
under the age of 60 (Goldberg et al., 1998). TRD is clearly understudied in the elderly, 
because late-life depression has higher rates of physical and cognitive comorbidity and age-
related pharmacodynamic/pharmacokinetic changes add greatly to the complexity of 
monitoring TRD (Cooper et al., 2011) 
2.2.3 Depression subtypes 
Despite efforts to elucidate if TRD could be classified as “a unique subtype of depression” 
(Fagiolini and Kupfer, 2003), no specific endophenotypes or biological markers have been 
solely associated with TRD. Moreover depressive subtypes such as atypical depression, 
psychotic depression, and bipolar depression have been associated with poor outcome and a 
higher degree of resistance to specific types of treatment or to treatment in general, or both. 
Thus, depression subtypes are important elements as they may influence the rate of TRD, its 
evaluation and management. For example, patients with bipolar disorder may be 
misdiagnosed as TRD due to their higher rate of MD compared to manic episodes (Gaynes 
et al., 2009; Kupfer et al., 2002). Depressed subjects with melancholia have a greater degree 
of response to TCAs and ECT (Fava, 1996, 2003) whereas atypical depression is known to be 
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more resistant to TCAs but not to MAOIs (Liebowitz et al., 1988; Quitkin et al., 1993; Thase 
et al., 1991). 
2.2.4 Severity of the disease and other comorbid psychiatric disorders  
Disease severity has been thoroughly associated with TRD (Souery et al., 2007; Dudek et al., 
2010) and patients with greater symptom severity were approximately 3 times less likely to 
remit than those with mild or moderate depression in the STAR*D study (Rush et al., 2008). 
Severe depression is usually associated with lower spontaneous remission rate, greater risk 
of recurrence and higher chronicity of the disease (Thase et al., 2000). Disease chronicity has 
been also associated with TRD with longer episodes and greater recurrence of episodes 
(Souery et al., 2007; Dudek et al., 2010). 
Comorbid anxiety is one of the most associated symptom coexisting with MD (Clayton et 
al., 1991) and thus is also one of the highest comorbidity of the disease associated with TRD 
(Gaynes et al., 1999; Souery et al., 2007; Dudek et al., 2010). Patients with melancholic 
features also appear more prone to develop TRD (Rush et al., 2008; Mc Grath et al., 2008). 
Obsessive-compulsive disorders, personality disorders, suicidal risk and substance of abuse 
(most of all is alcohol) are also among the greatest comorbidity associated with TRD (Souery 
et al., 2007; Kornstein et Schneider, 2001; Fagiolini et Kupfer, 2003; Sackeim, 2001). Finally, 
other medical conditions such as weight gain, diabetes, hypertension, hypothyroidism, 
chronic painful conditions are also considered as risk factors to develop TRD (Gaynes et al., 
2009; Kornstein et Schneider, 2001; Berlim and Turecki, 2007a) 
3. Animal models of depression and non-response/resistance to 
monoaminergic antidepressant 
Given the problems with current lines of antidepressant treatment in the clinic, it is 
incumbent upon basic research to yield novel methods of treatment. In order for basic 
research to provide potential advances, a critical first step is to create useful animal models 
with relevant phenotypic features to reveal treatment responsiveness. However, some of the 
original animal models designed to address this problem suffered from a flawed 
tautological approach in that they were based solely on responsiveness to known 
antidepressants. Since no genetic variants with high penetrance that cause depression are 
known, animal models have mainly relied on different means of chronically exposing 
rodents to stressful experiences, or sensory tract lesions such as in olfactory bulbectomy, to 
induce behavioral states that present depression-like signs and are responsive to chronic 
antidepressant treatment. 
3.1 Non-response/resistance in the unpredictable chronic mild stress model 
The oldest most commonly used paradigm to induce a depression-like state is chronic mild 
stress (CMS). Initial observations suggested that animals subjected to multiple stressors over a 
prolonged period of time reduced their intake of saccharine or sucrose, a potential behavioral 
model of anhedonia (Katz, 1982). Furthermore, this effect was selectively reversed by chronic 
treatment with the TCA imipramine (Katz, 1982). Further work was able to repeat this result 
using more mild stressors, such as periods of food and water deprivation, small temperature 
reductions and changes of cage mates (Willner, 2005; Willner et al., 1987). Following these 
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studies the CMS procedure, and modified versions such as chronic unpredictable stress (CUS 
or UCMS), became commonly used and much work demonstrated that other depression-like 
changes were induced in animals, such as decreased sexual and aggressive behavior, 
decreased self-care, and altered sleep patterns (Willner, 2005). Furthermore these behaviors are 
all reversible by chronic, but not acute, treatment using multiple classes of antidepressants 
(Surget et al., 2008). While historically potential pitfalls of the CMS procedure are that it is 
notoriously labor intensive, and that there has been some difficulty in getting the procedure 
established and the results replicated across laboratories (Nestler et al., 2002), the modified 
versions of the CMS have proven more useful. 
Recently, there have been some reports using CMS or variants to model treatment resistance 
in rodents. In one study, CMS significantly decreased sucrose consumption and the 
proliferation of adult hippocampal neural progenitors (Jayatissa et al., 2006). Following 
chronic treatment with a SSRI (escitalopram), the subjects were retested for sucrose 
consumption. A bimodal distribution was found where one group recovered (increased 
sucrose consumption) while another refracted treatment (no increase in sucrose 
consumption). Interestingly, there was a correlation between the animals in the group that 
recovered with a reversal of the decreased proliferation that was absent in the group 
resistant to treatment (Jayatissa et al., 2006). More recently, follow-up work has taken a 
proteomic approach in an attempt to find molecular differences in the ventral hippocampus 
between responders and non-responders (Bisgaard et al., 2007). Another study 
demonstrated that if animals are on a high fat diet during multiple UCMS procedures they 
become resistant to treatment with a SSRI (fluoxetine) (Isingrini et al., 2010). 
3.2 Non-response/resistance in the social interaction model 
A distinct procedure that has gained traction is the usage of a social defeat model. In this 
paradigm a mouse is forced into the territory of a mouse from a larger, more aggressive 
strain leading to an interaction resulting in intruder subordination. Repeated defeats over 10 
days can result in a long lasting reduced social interaction, sexual dysfunction, sleep 
dysregulation, anxiety, metabolic deficits and anhedonia (Berton et al., 2006; Tsankova et al., 
2006; Krishnan et al., 2007; Krishnan and Nestler, 2008). Interestingly, following the social 
defeat procedure there remains a large variance in behavior outcomes in spite of using an 
inbred mouse strain (C57BL/6). Some animals display a resistance to social defeat 
(resilience) while others are susceptible (determined by interaction with a social target 
relative to an empty enclosure). If animals are separated based on this measure, susceptible 
mice demonstrate decreased sucrose intake, a blunted circadian rhythm, and conditioned 
place preference to cocaine (Krishnan et al., 2007). Furthermore, phenotypes induced by 
social defeat in susceptible mice can be reversed by antidepressant treatment (Tsankova et 
al., 2006). Given that molecular mechanisms for resilience to the stressful procedure are now 
being worked out (Krishnan et al., 2007; Vialou et al., 2010), it would be intriguing to see if 
similar pathways are necessary for mediating response to antidepressants. 
3.3 Non-response/resistance in the corticosterone model 
A third procedure for inducing a depression-like state in animals is administration of 
chronic glucocorticoids in order to mimic the effects of chronic stress. A significant 
proportion of depressed patients display altered activity of the HPA axis, and stress 
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generally leads to hypersecretion of corticosteroids, which imposes an increased risk for 
depression (Carroll et al., 1981; Nemeroff et al., 1984; Strohle and Holsboer, 2003; Brown et 
al., 2004; de Kloet et al., 2005; Antonijevic, 2006; Leonardo and Hen, 2006, 2004). Chronic 
treatment of rodents with corticosterone effectively induces multiple anxiety- and 
depression-like changes in behavior, neurochemistry and brain morphology (Ardayfio and 
Kim, 2006; Gourley et al., 2008; Murray et al., 2008; David et al., 2009). Behaviorally, 
depression-related changes include suppression of sucrose intake and decreased self-care 
(Gourley et al., 2008; David et al., 2009), while anxiety-related changes include increased 
latency to emerge into the light compartment in the light/dark test, decreased time, entries 
and percent distance in the center of an open field and increased latency to take a bite of 
food in the novelty suppressed feeding (NSF) test (Ardayfio and Kim, 2006; David et al., 
2009). Behaviorally, approximately 85% of C57BL/6 mice demonstrate anxiety and 
depression-related signs in response to chronic corticosterone, suggesting that, similar to 
social defeat, there is a small population that is resilient to the manipulation (David et al., 
2009; David unpublished data). Interestingly, animal subjects that participate in the Novelty 
Suppressed Feeding test, a paradigm sensitive to chronic antidepressant, do tend to show a 
bimodal distribution in response to antidepressant treatment, suggesting a responder and 
non-responder divide (Samuels et al., 2011). By anthropomorphic analogy, an animal was 
considered as a responder to fluoxetine when its behavioral response was improved by at 
least 50%. Similarly to what is observed in humans, it was shown in this model that 30% of 
the animals did not respond to fluoxetine. These preliminary data argue for the validity of 
the CORT model in assessing non-response to antidepressants. Furthermore, we propose 
here a preclinical model for studying non-response/resistance, based on what has been 
developed in clinic by international consensus statement on major depressive disorder (Nutt 
et al., 2010) and proposed in therapeutic (Figure 1).  
3.4 Current hypotheses on the molecular and cellular bases of  
non-response/resistance to antidepressants 
It is still not clear why some animals are non-responders to antidepressants in these models. 
However growing evidence suggests that part of the answer lies in the neurogenesis 
process. At the cellular level, it has been known for several years that antidepressants 
increase hippocampal neurogenesis (Malberg et al., 2000) and that some of their behavioral 
effects require adult neurogenesis (Santarelli et al., 2003; Surget et al., 2008; Wang et al., 
2008, David et al., 2009). However, in rodents deprived of adult neurogenesis, some 
behavioral effects of chronic antidepressant treatments remained unaltered suggesting the 
existence of neurogenesis-dependent and neurogenesis-independent mechanisms (Surget et 
al., 2008) (Figure 2). The delayed onset of antidepressants response in MD patients led to the 
hypothesis that their efficacy results from restoration of functional neural networks which 
are altered in MD patients (Duman et al., 2000). Thousands of new neurons are continuously 
produced every day in the mammal adult brain, specifically in the dentate gyrus (DG) of the 
hippocampus and the olfactory bulb (OB) (Lledo et al., 2006). In the DG, stem cells give rise 
to progenitor cells that migrate to the granular and molecular layers and differentiate into 
excitatory granule neurons. Neuroblasts fated for the adult OB are produced in the walls of 
the lateral ventricles (subventricular zone: SVZ). They migrate tangentially toward the core 
of the OB, forming the rostral migratory stream. Upon reaching the OB, adult born 
neuroblasts migrate radially within the lamina of the OB to reach their final position and 
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start to differentiate. In several animal models of depression, including the CORT model, 
chronic antidepressant treatments accelerate the three phases of hippocampal neurogenesis 
i.e. proliferation, maturation and survival of the newly born neurons (Wang et al., 2008). 
Interestingly, in some of the neurogenesis readouts (proliferation and maturation), the SSRI 
fluoxetine is much more effective in corticosterone-treated animals than in normal animals, 
suggesting that stress may increase the dynamic range in which fluoxetine can exert its 
effects on specific stages of neurogenesis. In humans, evidence suggests higher levels of 
neural progenitor cells in the DG of depressed individuals treated with SSRIs compared to 
untreated patients, who also had 50% fewer dividing cells than controls (Boldrini et al., 
2009). Together these data are consistent with the hypothesis that part of antidepressant 
response is the stimulation of neurogenesis whereas non-response/resistance could 
potentially be explained by a lower capacity for neurogenesis. 
 
Fig. 1. Algorithm for developing animal model of resistance, based on the CORT model 
(David et al., 2009) 
At the molecular level, Brain-derived neurotrophic factor (BDNF), a member of the 
neurotrophin family, has been identified as a major candidate involved in the regulation of 
adult neurogenesis in the DG of the hippocampus and the OB (Duman and Monteggia, 2006; 
Bath et al., 2011). Indeed, chronic antidepressant treatments produce an increase in 
hippocampal BDNF levels (Nibuya et al., 1995; Duman & Monteggia, 2006) and a direct 
infusion of BDNF into the DG exerts antidepressant-like effects (Shirayama et al., 2002; 
Hoshaw et al., 2005; Kozisek et al., 2008). These observations raised the possibility that 
BDNF and activation of its high affinity receptor TrkB could be relevant markers of 
antidepressants response in MD patients, and blunted BDNF neurotransmission a marker of 
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non-response/resistance to these drugs. Among the main signaling pathways implicated in 
the pathophysiology of MD and antidepressant response, the β-arrestin-signaling cascade 
has recently gain attention due to the fact that BDNF may indirectly regulate this pathway. 
To date, four functional members of the arrestin gene family have been cloned, two arrestins 
(visual arrestin and cone arrestin) are expressed almost exclusively in the retina whereas 
two β-arrestins, β-arrestin 1 and 2, are ubiquitously expressed proteins with high levels in 
the brain (Luttrell and Lefkowitz, 2002). β-arrestins display two distinct roles. They 
constitute important proteins involved in the internalization of various receptors including 
5-HT and DA receptors (Li and Jope, 2010). They are also scaffolds for G-protein-coupled 
receptors (GPCR) to recruit signaling molecules, one of the most fundamental cellular signal 
transduction processes known. Through this mechanism, β-arrestins activate intracellular 
kinases such as the protein kinase B (Akt) (involved in cell survival and proliferation), the 
extracellular-regulated kinase (Erk) (involved in cell proliferation, differentiation and 
survival) and the Glycogen Synthase Kinase-3β (GSK-3β) (involved in energy metabolism 
and neuronal cell development) (Lefkowitz and Shenoy, 2005). A substantial body of 
evidence has accumulated indicating that β-arrestins play a major role in the 
pathophysiology of mood disorders, as well as in the mechanisms of action of 
antidepressants. In human, for example, changes in β-arrestins expression are detected in 
MD patients and in response to stress while various antidepressant drugs reverse these 
changes (Avissar et al., 2004). Overall, these data suggest that β-arrestins could be major 
molecular determinants of the effects of fluoxetine, and, more generally, of SSRIs and SNRIs. 
β-arrestin-1 protein and mRNA levels in mononuclear leukocytes of untreated patients with 
MD are significantly lower than those of healthy subjects and these levels are significantly 
correlated with the severity of depressive symptomatology (Avissar et al., 2004; Schreiber et 
al., 2009). The low β-arrestin-1 protein and mRNA levels were alleviated by antidepressant 
treatments, whereby normalization of β-arrestin-1 preceded, and thus predicted, clinical 
improvement. In rodent, SSRIs, SNRIs but also non-selective reuptake inhibitors increase β-
arrestin-1 levels. Molecular functions of β-arrestins place them in pathways associated with 
response to lithium, a drug currently used to treat bipolar disorders (Beaulieu et al., 2008). 
Caron’s group had hinted that β-arrestin KO mice were unable to scaffold a signaling 
complex. Hence, in these mutants, lithium failed to activate Akt, leading to a loss GSK3 
inhibition and to a disruption of antidepressant-like responses. Several sources of evidence 
suggest that SSRIs promote inhibitory control of GSK3 in several brain regions including the 
frontal cortex, the hippocampus and the striatum of naïve mice exhibiting a normal, non-
depressed phenotype (Emamian et al., 2004; Li et al., 2007; Beaulieu et al., 2008) suggesting 
that inhibition of this protein play a major role in the antidepressant response. Consistent 
with this hypothesis, GSK3 inhibitors produce antidepressant-like effects in the mouse FST 
(Gould et al., 2004). Similar results were observed in GSK3 mutant mice, which display a 
50% reduction in the expression of this kinase (Hoeflich et al., 2000). With respect to β-
arrestin-2, recent findings show that this protein might be also involved in neurogenesis-
dependent and –independent mechanisms (David et al., 2009; Li et al., 2009). Using the 
“CORT model”, it was shown that fluoxetine reversed the neurogenic deficit induced by 
glucocorticoid elevation and restored expression of β-arrestin-1 and -2 that were blunted by 
chronic corticosterone (David et al., 2009). These observations further confirm the possibility 
that β-arrestins are necessary for antidepressant to exert their therapeutic activity. 
Accordingly, deficient mice for β-arrestin-2 displayed a reduced response to fluoxetine 
(David et al., 2009). Together, these data led us to postulate that decrease in the expression 
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and/or functional activity of molecular components of β-arrestin-signaling cascades 
represent biomarkers of non-response and resistance to antidepressant.  
 
Fig. 2. Chronic fluoxetine reverses the behavioral and neurogenic deficits induced by 
chronic corticosterone exposure, showing neurogenesis-dependent and neurogenesis-
independent effects (Adapted from Rainer et al., 2009). 
4. New antidepressant strategy to counteract resistance: The triple reuptake 
inhibitors (TRIs) 
Numerous therapeutic strategies have been proposed to alleviate TRD, including 
augmentation strategies such as the combination of SSRIs with bupropion or antipsychotics, 
combination of drugs with ECT or somatic treatments such as repetitive transcranial 
magnetic stimulation (rTMS), vagus nerve stimulation (VNS), and deep brain stimulation 
(DBS), or new molecules including the triple reuptake inhibitors (TRIs).  
Signs and symptoms of depression can be linked to one or more monoaminergic systems, 
specifically the 5-HT, the NE and the DA systems. There are considerable reciprocal 
interactions between these monoaminergic neurons that can produce counterproductive 
effects (Guiard et al., 2008). When using a SSRI, for example, 5-HT transmission is enhanced, 
but at the same time there is a dampening of the activity of NE and DA neurons through 
inhibitory 5-HT2A and 5-HT2C receptors, respectively. This could explain the residual 
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symptoms of fatigue, lack of energy, and anhedonia, often observed after patients present an 
overall positive response to a SSRI (Blier and Briley, 2011). Using dual-acting agents such as 
duloxetine, milnacipran or venlafaxine would result in an additional increase in NE activity. 
However, a risk inherent in increased NE activity is that of provoking anxiety. Hence, the 
question can be asked as to whether the remaining symptoms observed with SSRI/SNRIs 
are responsible for a non-response/resistance to these antidepressants or if the lack of 
significant therapeutic activity results from dysfunction in other neurotransmitters such as a 
blunted DA neurotransmission? In this context, a new generation of antidepressants named 
the triple reuptake inhibitors (TRIs) has been developed with the hope of offering a 
clinically relevant advantage over currently available medications (Guiard et al., 2009). Since 
TRIs simultaneously enhance extracellular levels of 5-HT, NE and DA neurotransmissions in 
various brain regions, this class of antidepressants could exert their therapeutic activity by 
treating more symptoms of MD and/or by attenuating some side effects observed in 
response to traditional antidepressants. Accordingly, converging lines of evidence indicate 
that drugs enhancing dopaminergic neurotransmission can diminish anhedonia (Dunlop 
and Nemeroff, 2007), a symptom that responds poorly to SSRIs (Shelton and Tomarken, 
2001). Clinical studies indicate that it is possible to achieve an antidepressant action by 
enhancing DA. Moreover, the dopamine reuptake inhibitor bupropion has also 
demonstrated antidepressant activities (Tremblay and Blier, 2006) and its use in 
combination with SSRIs enhances the antidepressant response in resistant patients (Zisook 
et al., 2006).  
4.1 Preclinical properties of TRIs 
A number of compounds with the ability to bind and block all three monoamine 
transporters have been developed with the hope to produce greater symptomatic relief than 
single- or dual-acting agents and consequently to reduce non-response and resistance. DOV 
Pharmaceutical, Inc. is the first company having provided in vitro and in vivo preclinical 
data with their triple reuptake inhibitors DOV216303, DOV21947 (amitifadine) and 
DOV220075 (bicifadine). New molecules have followed such as NS2330 (tesofensine, 
GlaxoSmith-Kline/NeuroSearch), SEP225289 (Sepracor Inc.), CNS-1 and CNS-2 (Albany 
Molecular Research Institute Inc), PRC-025, PRC-050, PRC-200SS (Mayo Foundation), 
JNJ7925476 (Johnson & Johnson Pharmaceutical Research & Development), WF-23 (Eli 
Lilly), JZAD-IV-22 (PsychoGenics) and more recently TP1 (Luye Pharmaceutical Group). 
Others compounds will undoubtedly emerge in a near future. In 2010-2011, the structure 
activity relationship (SAR), of at least eleven new TRIs, has been reported (Hache et al., 
2011).  
4.1.1 Behavioral effects of TRIs 
Behavioral data clearly demonstrated the antidepressant-like effect of TRIs that act by 
increasing the time of mobility and/or by reducing the time of immobility in the FST or the 
TST. Among the TRIs tested, JNJ7925476 appears the most potent since a low dose of this 
agent (0.3 mg/kg; s.c.) produced antidepressant-like effects. In term of efficacy (i.e., maximal 
effect), compounds such as PRC200-SS (10mg/kg; ip), D-142 or D-161 produced a greater 
percentage of increase in the time of mobility or decrease in the time of immobility than the 
others TRIs (Aluisio et al., 2008; Dutta et al., 2008; Liang et al., 2008; Dutta et al., 2011). 
Interestingly, JNJ7925476 and PRC200-SS display the highest affinity for SERT and NET 
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suggesting that this double action is an important prerequisite to produce optimal 
behavioral responses. Since DA is known to enhance locomotor activity, the possibility 
cannot be excluded that TRIs increased the time of immobility in these various studies, 
through a psychostimulant effect. In various studies, however, TRIs did not modify 
locomotor activity at doses that produce antidepressant-like effects (Tian et al., 2011; Aluisio 
et al., 2008; Liang et al., 2008; Shaw et al., 2007; Skolnick et al., 2003), thereby ruling out the 
possibility that the antidepressant-like activity detected does not appear to be from “false-
positive” results. An important drawback in the development of antidepressants is the fact 
that the new compounds are tested after acute administration in naïve, non-depressed 
animals. Their chronic use in animal models is more appropriate and provides more 
informative results to determine whether or not new pharmacological agents are worth 
being tested in clinical trials. A recent study in bulbectomized rats provided some 
interesting results. In this model, a 14-day regimen of the TRI DOV216303 normalized 
bulbectomy-induced hyperactivity in the open field, similar to the effect of imipramine at 
the same dose (Breuer et al., 2008). Inevitably, further studies in these animal models are 
required to determine the potential of TRIs over SSRIs and SNRIs in terms of quality of 
antidepressant response.  
4.1.2 Neurogenic effects of TRIs 
As above-mentioned (paragraph 3.4), a number of studies have demonstrated that SSRIs 
increase cell proliferation and neurogenesis in the DG of the hippocampus of naive 
(Marcussen et al., 2008; Sairanen et al., 2005; Santarelli et al., 2003; Malberg et al., 2000) or 
depressed rodents (David et al., 2009; Malberg and Duman, 2003). It was also reported that 
catecholamines (NE and DA) might stimulate this process. For example, NRIs and SNRIs 
have been shown to increase the local expression of neurotrophic factors including BDNF 
(Nibuya et al., 1995; Larsen et al., 2008; Russo-Neustadt et al., 2004) and adult hippocampus 
neurogenesis in the DG (Malberg et al., 2000). In a recent study aimed at comparing 
monoaminergic compounds with different pharmacological profiles (at doses that have been 
shown to produce antidepressant-like effects in behavioral models), it was demonstrated 
that sustained administration of the reuptake inhibitors venlafaxine and imipramine 
increased BDNF mRNA expression after 7 and 14 days of administration respectively, while 
the SSRI fluoxetine had no effect (Larsen et al., 2007). It is thus possible that the activation of 
the serotonergic and noradrenergic neurotransmitter system activates different downstream 
cascades that are both able to increase the transcription of BDNF. Whether or not this 
apparent effect favors antidepressant response has yet to be demonstrated. Importantly, the 
hippocampus receives a sparse dopaminergic innervation from the ventral tegmental area 
(Scatton et al., 1980), raising the possibility that DA and related receptors play a limited role 
in the local regulation of BDNF expression and neurogenesis. However, dopaminergic 
denervation in animals causes a dramatic reduction in the number of proliferating cells in 
the hippocampus (Hoglinger et al., 2004) while the stimulation of DA receptors with 
selective D2 agonists has recently been shown to enhance neurogenesis in the DG of the 
hippocampus (Hoglinger et al., 2004, Yang et al., 2008). In a recent series of in vivo 
experiments, it has been shown that the Cytokine Ciliary Neurotrophic Factor (CNTF), 
abundant in astrocytes close to dopaminergic terminals, constitutes an endogenous 
regulatory component of D2-receptor-dependent neurogenesis in DG (Yang et al., 2008; 
Mori et al., 2008) suggesting that TRIs might be stronger on neurotrophic factor gene 
expression, neural plasticity, and neurogenesis than SSRIs, NRIs and SNRIs. Using in situ 
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hybridization, an initial study showed that treatment with the TRI NS2330 (Tesofensine), for 
5 and 14 days had no effect on BDNF expression in the granular cell layer, while increasing 
its expression by 35 % in the CA3 after 14 days (Larsen et al., 2007). Furthermore, NS2330 
stimulated the number of neuroD-positive cells after 14 days treatment and the nuclear 
marker of proliferation Ki67, confirming the antidepressant potential of this novel agent 
(Larsen et al., 2007). Although these results revealed a strong effect of NS2330, the net effect 
of blockade of each of the monoamine reuptake sites remains unknown. Further studies are 
truly necessary to dissect the contribution of each monoamine uptake target on the 
regulation of BDNF or others neurotrophic factors gene expression. It is possible that the 
stimulation of the expression of various neurotrophic factors such as BDNF and CNTF 
induced by the concomitant enhancement of central 5-HT, NE and DA transmission, might 
contribute to shorten the delay of action of traditional antidepressants drugs. 
4.2 Clinical properties of TRIs 
TRIs are in process of development (Millan, 2009) and most are now in Phase II clinical 
trials. A small citalopram-controlled trial of DOV216303 in severely depressed patients 
yielded significant improvements in Hamilton Depression Rating Scale (HAM-D) scores in 
both groups at one-week and two week time points (Skolnick et al., 2006). DOV 
Pharmaceutical has recently reported the results of a multi-centric, randomized, double-
blind, placebo-controlled study with amitifadine (DOV21947) in 61 patients with MD (Tran 
et al., 2011). For the primary outcome measure, treatment with amitifadine was associated 
with a significantly greater improvement in the MADRS and CGI-I total score at week 6 
compared with placebo. In addition, a significantly greater remission rate for the CGI-S was 
observed with amitifadine compared with placebo at week 6. This study also showed that 
amitifadine was efficacious in improving anhedonia, a core symptom of depression that is 
presumed to be related to a hypodopaminergia. Despite these encouraging data, it is still not 
clear whether non-response and/or resistance to TRIs is lower than that observed with 
SSRIs or SNRIs. Specific clinical trials should address this question in the future. 
Nevertheless, several arguments allow for optimism. 75% of patients suffering from 
depression are found to report somatic symptoms, including various types of pain such as 
headaches, stomach pain, back pain, and vague, poorly localized pain (Fava, 2003). A recent 
study has shown that responders who have not achieved remission have significantly more 
somatic symptoms than remitters following 8 weeks of treatment with fluoxetine. These 
data may suggest that antidepressants that are particularly effective in the treatment of pain 
and painful physical symptoms may yield higher remission rates in major depressive 
disorder (Hache et al., 2011). In addition, it has been suggested that presence of pain may be 
an indicator of MD that may have poorer treatment outcome with an initial SSRI (Leuchter 
et al., 2010). Acute and chronic pains may result from reduced levels of endogenous 5-HT, 
NE and DA activities, at both the spinal and supraspinal levels (Ren and Dubner, 2002). 
Thus, one would expect a better efficacy of dual-or triple-acting agents over selective 5-HT 
or NE reuptake inhibitors in analgesia (Hache et al., 2011). Several open-label randomized 
controlled clinical trials, meta-analyses, and systematic reviews have confirmed the clinical 
efficacy of selected antidepressants in persistent pain conditions (Dharmshaktu et al., 2011). 
Clinical studies have corroborated that bicifadine is an effective analgesic in the treatment of 
postoperative pain (Krieter et al., 2008). In a second study, the TRI NS7051, has shown 
comparable antinociceptive properties to tramadol confirming the interest of these 
antidepressants in the relief of pain (Munro et al., 2008). The molecule has undergone several 
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phase II and III trials for the treatment of pain, including acute postsurgical pain and chronic 
low back pain, and is being evaluated for painful diabetic neuropathy (clinical trial.gov).  
5. Conclusion 
In summary, current antidepressant treatments are not sufficient, as many patients do not 
respond. Future basic and clinical research will need to take new approaches to advance the 
understanding and discover new methods for treatment-resistant depression. While most 
animal models of depression have focused on pharmacological validity, this has led to an 
overemphasis on mechanisms underlying currently used drugs rather than the discovery of 
new targets that could benefit patients suffering from treatment-resistant depression. 
Furthermore, using animal models will be valuable in providing a translational framework 
to study SSRI insensitivity, and validation of any findings in humans as potential 
biomarkers for treatment responsiveness will pave the way to break a tradition of using 
SSRI sensitive behavioral assays to interrogate novel approaches for relieving depressive 
phenotypes. 
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